120 filings
8-K
NKTX
Nkarta Inc
27 Jun 24
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis
6:45am
8-K
NKTX
Nkarta Inc
13 Jun 24
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
4:22pm
10-Q
2024 Q1
NKTX
Nkarta Inc
Quarterly report
9 May 24
4:14pm
8-K
NKTX
Nkarta Inc
9 May 24
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
4:04pm
ARS
2023 FY
NKTX
Nkarta Inc
25 Apr 24
Annual report to shareholders
4:35pm
DEFA14A
ykfst7
25 Apr 24
Additional proxy soliciting materials
4:34pm
8-K
cphlj3msctkc
28 Mar 24
Other Events
4:08pm
424B5
uqbi2b09o72acl
25 Mar 24
Prospectus supplement for primary offering
8:15pm
8-K
efxjag840s1s oef
25 Mar 24
Regulation FD Disclosure
6:05am
8-K
ulxv1np7kej
21 Mar 24
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
4:15pm
8-K
sjgbhd
8 Jan 24
Regulation FD Disclosure
8:50am
S-8
a590s3a1zw
3 Jan 24
Registration of securities for employees
4:15pm
8-K
edyzjj22y95ombc
9 Nov 23
Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
4:06pm
8-K
3qtxkh0z 150
17 Oct 23
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
7:06am
8-K
5r1ksw0f 83msx93
16 Oct 23
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
4:07pm